| ID | 10279 |
| Vaccine Name | COVIVAC |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Recombinant viral vector |
| Vaccine Status | Phase 2 |
| Manufacturer | Icahn School of Medicine, Mahidol University |
| Year of Manufacturing | 2021 |
| Manufacturing Country | Thailand |
| Age | 18 - 75 years |
| Dosage | 2 doses 28 days apart |
| Administration Route | Intramuscular |
| Adjuvant | CpG 1018 |
| Target Strain | Spike protein of SARS-CoV-2 virus |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | ADAPTCOV, NDV-HXP-S vaccine, , HXP-GPOVac, Patria, ButanVac |
| PMID | NA |
| Clinical Trial ID | NCT04764422 |
| Reference Link | https://clinicaltrials.gov/show/NCT04764422 |
| Additional Links | NA
|